# cancer Biophysics

Title Page

Title: An Electrochemical Hypothesis for Cancer: GABAergic Dysregulation, Alpha-Ketoglutarate Accumulation, and Circadian Vulnerability in Oncogenic Transformation

Author:
Il Woong Choi
Korea University, Seoul, Republic of Korea
Email: iwchoikr@gmail.com

Corresponding Author:
Il Woong Choi
34A, Windmill Road, Oxford, United Kingdom OX3 7BX
Email: iwchoikr@gmail.com



Abstract

Cancer arises through progressive genetic and epigenetic alterations, yet fundamental questions remain regarding what creates permissive conditions for oncogenesis. This paper proposes an electrochemical framework linking cancer to disrupted GABAergic metabolic regulation systems via a novel thermodynamic mechanism. We hypothesize that cancer is not merely a disease of uncontrolled growth, but a reversion to a primordial, reductive metabolic state driven by the accumulation of a fundamental, quantized electrochemical deficit. We propose that phenotypes with deficient GABA pathway function experience simultaneous metabolic stagnation (thermodynamic inhibition via accumulated alpha-ketoglutarate) and "bio-electric instability" (circadian-dependent charge dysregulation). Central to this hypothesis is the role of alpha-ketoglutarate not just as a metabolite, but as a "capacitive sink" for undischarged bio-electric potential, and GABA as the critical "gating mechanism" for this charge. When these systems fail, particularly during the bio-electric nadir of the circadian cycle, a specific, sub-threshold charge debt accumulates, forcing the cell into a proliferative state to dissipate this electrochemical burden. This framework integrates metabolic reprogramming, circadian disruption, and genomic instability into a unified model, offering testable predictions for therapeutic interventions targeting GABAergic restoration.

Keywords: cancer, GABA metabolism, circadian rhythm, alpha-ketoglutarate, electrochemical regulation, metabolic debt



Table of Contents

Introduction

The Hypothesis

Core Propositions

The Electrochemical Mechanism: A Matter of Quantized Debt

Alpha-Ketoglutarate: The Capacitive Charge Sink

GABA: The Voltage Gating Mechanism

Circadian Integration and the Bio-Electric Nadir

Adrenergic Signaling Dysregulation

Alignment with Established Cancer Biology

Genomic Instability

Metabolic Reprogramming

GABAergic Signaling in Tumors

Testable Predictions

Biomarker Patterns

Genetic Associations

Intervention Studies

Animal Model Predictions

Therapeutic Implications

Prevention Strategies

Treatment Enhancement

Limitations

Conclusions

References



Introduction

Cancer develops through the accumulation of genetic alterations enabling sustained proliferative signaling, growth suppressor evasion, cell death resistance, and metastatic potential (1). While specific oncogenes and tumor suppressors have been identified, fundamental questions persist: Why do mutations accumulate non-randomly? What creates permissive cellular environments for transformation? Why do circadian disruption and chronic stress consistently elevate cancer risk (2,3)?

Gamma-aminobutyric acid (GABA) functions beyond its canonical neurotransmitter role. GABA metabolism intersects central carbon metabolism through the GABA shunt, bypassing two tricarboxylic acid (TCA) cycle steps while generating succinate and consuming alpha-ketoglutarate (4). This pathway appears throughout biology, suggesting fundamental bioenergetic rather than solely neuromodulatory functions (5). Emerging evidence reveals functional GABA signaling in cancer cells themselves, modulating proliferation, migration, and therapeutic resistance (6,7).

We propose that cancer susceptibility reflects a failure of GABAergic charge regulation systems, specifically a collapse of the cell’s ability to manage a discrete, fundamental quantum of metabolic potential. This is not a gross failure of energy production, but a specific inability to resolve a minute, accumulating "electrochemical debt." Deficient GABA pathway function creates two convergent metabolic stresses: accumulated alpha-ketoglutarate ("metabolic stagnation") and circadian-dependent charge dysregulation ("bio-electric instability"). Together, these produce genomic instability and remove inhibitory control over adrenergic proliferative signaling.

The Hypothesis

Core Propositions

Cancer arises from a quantized electrochemical deficit: Oncogenesis is driven by the accumulation of a specific, sub-threshold metabolic charge debt. This debt accumulates when the cell cannot efficiently discharge reductive potential during low-energy phases.

Dual GABAergic metabolic failures drive this state: "Metabolic stagnation" (alpha-ketoglutarate accumulation) and "bio-electric instability" (circadian charge dysregulation) are the macroscopic manifestations of this microscopic charge imbalance.

Alpha-ketoglutarate acts as a capacitive sink: Accumulated alpha-ketoglutarate represents the physical storage of this unresolved charge debt, forcing the cell into reductive biosynthesis to manage the potential.

GABA acts as the voltage regulator: GABA signaling establishes the specific electrochemical threshold required to gate this charge. Its failure allows the debt to accumulate to pathogenic levels.

Circadian disruption creates vulnerability windows: The nighttime or "bio-electric nadir" represents the period of maximum vulnerability when this charge debt naturally peaks and must be resolved (9,10).

The Electrochemical Mechanism: A Matter of Quantized Debt

Recent theoretical advances suggest that cellular metabolism does not operate on a continuous gradient but rather manages discrete "packets" of electrochemical potential. In healthy cells, these potentials are discharged rhythmically. However, under conditions of stress—specifically those mimicking a primordial, low-oxygen, or non-photic environment—a minute but persistent "charge debt" begins to accumulate.

Alpha-Ketoglutarate: The Capacitive Charge Sink

Alpha-ketoglutarate (α-KG) occupies a critical metabolic position as a TCA cycle intermediate and cofactor for dioxygenases (13). In our hypothesis, α-KG is not merely a metabolite; it is the cellular "capacitor" for this accumulating charge debt.

When the cell faces a thermodynamic bottleneck—unable to fully oxidize carbon due to the accumulating electrochemical deficit—it cannot proceed through the standard oxidative TCA cycle. The "extra" reductive potential must go somewhere. It is dumped into α-KG.

Consequently, α-KG accumulates. Instead of being burned for fuel, this "charged" α-KG is diverted into reductive carboxylation pathways (reversing the TCA cycle) to build fatty acids and biomass. This explains the "Warburg Effect" and the diversion of glucose into biomass: the cell is not simply growing; it is frantically building physical mass to sequester the excess electrochemical charge that it cannot discharge energetically. The oncometabolite 2-hydroxyglutarate (produced by IDH mutations) can be viewed as a desperate, pathological attempt to chemically stabilize this "overcharged" α-KG capacitor (17,18).

GABA: The Voltage Gating Mechanism

If α-KG is the capacitor, GABA is the gatekeeper. To discharge this specific, quantized unit of metabolic debt, the cell requires a precise electrochemical environment—specifically, a regulated depolarization or "low voltage" state that permits the flow of these subtle currents.

GABA is evolutionarily optimized for this role. By modulating chloride ion flux and membrane potential, GABA signaling fine-tunes the cellular voltage to the exact frequency required to "ground" this metabolic charge. In a healthy state, GABAergic activity opens these gates rhythmically (likely during sleep), allowing the accumulated debt to dissipate.

In cancer, this GABAergic gating fails. The membrane potential remains too high or effectively "locked," preventing the discharge of the debt. The "static" builds up. The cell, sensing this dangerous accumulation of potential, reverts to its ancient survival program: it uncouples its mitochondria (Warburg effect) and ramps up proliferation to physically divide and dilute the electrochemical burden.

Circadian Integration and the Bio-Electric Nadir

GABA pathway function shows profound circadian dependence. Left GABA pathway deficiency manifests as "bio-electric instability"—charge dysregulation occurring specifically during nighttime when protective regulatory systems should activate.

During the solar day, high energetic flux masks this subtle deficit. However, during the "bio-electric nadir"—the phase corresponding to nighttime or deep rest—the cell relies on intrinsic electrochemical buffering to maintain stability. It is here that the "darkness stress" manifests. Without the external drive of high-energy metabolism, the 1/32 quantum of charge debt becomes significant.

If GABAergic gating is dysfunctional during this window, the debt is not cleared. It compounds. This explains why shift work and circadian disruption are such potent carcinogens (19-21): they repeatedly force the cell into active phases without allowing the necessary "electrochemical discharge" period, leading to a chronic accumulation of the deficit.

Adrenergic Signaling Dysregulation

Chronic stress substantially elevates cancer risk, mediated largely through sustained catecholamine release (27). β-adrenergic signaling promotes tumor growth, metastasis, angiogenesis, and therapeutic resistance (11,28).

Hypothesis contribution: Normal GABAergic regulation maintains pulsatile rather than sustained adrenergic signaling through inhibitory control mechanisms. When GABA pathways fail, this inhibitory control disappears. This allows continuous β-adrenergic receptor activation.

From an electrochemical standpoint, sustained adrenergic signaling maintains the cell in a "high-tension" state, preventing the necessary relaxation/depolarization required to discharge the metabolic debt. The cell is stuck in a "fight or flight" energetic mode, accumulating debt that it can never pay off, driving it relentlessly toward transformation.

Alignment with Established Cancer Biology

Genomic Instability

Mechanism 1: Alpha-ketoglutarate disrupts epigenetic regulation
Accumulated alpha-ketoglutarate dysregulates TET enzymes controlling DNA methylation (14). This is not accidental toxicity; it is the electrochemical distortion of the nuclear environment. The altered redox potential prevents the proper "resetting" of epigenetic marks, locking the genome into a primitive, proliferative configuration.

Metabolic Reprogramming

Warburg effect connection: Aerobic glycolysis diverts carbon from TCA cycle oxidation (38). This is the cellular response to the "capacitive overload" of α-KG. Unable to force more current through a charged system, the cell diverts flow into reductive pathways.

GABAergic Signaling in Tumors

Multiple cancer types express functional GABA receptors (39-42). This is often viewed as paradoxical. However, under this hypothesis, it is a compensatory attempt. The tumor cell, burdened by immense electrochemical debt, upregulates GABA receptors in a desperate attempt to re-establish the "gating" mechanism and discharge its potential.

Testable Predictions

Biomarker Patterns

Prediction 1: Individuals at high cancer risk should exhibit elevated plasma alpha-ketoglutarate, particularly during evening/nighttime hours, representing the uncleared "charge inventory."

Prediction 2: Disrupted circadian profiles of GABA metabolites will correlate with the magnitude of the electrochemical deficit.

Genetic Associations

Prediction 4: Polymorphisms in GABA metabolic enzymes (GAD1, ABAT) and circadian genes (PER1-3, CRY1-2) will show synergistic effects on cancer risk, representing the combined failure of the "gate" (GABA) and the "timing" (Circadian) of charge resolution.

Intervention Studies

Prediction 6: GABAergic modulation affects cancer outcomes. GABA-A positive allosteric modulators administered during the "bio-electric nadir" (evening) will reduce cancer incidence by facilitating the discharge of the accumulated metabolic debt.

Prediction 9: Chronotherapy enhances treatment efficacy. Timing treatments to coincide with the natural windows of electrochemical discharge may bypass the tumor's resistance mechanisms.

Therapeutic Implications

Prevention Strategies

1. GABAergic restoration during vulnerability windows: Low-dose GABA-A positive allosteric modulators administered evening/nighttime in high-risk individuals.

2. Metabolic interventions: Strategies to manually "drain" the alpha-ketoglutarate sink, potentially via glutaminase inhibition or metabolic uncoupling agents that mimic the natural discharge of the debt.

Treatment Enhancement

3. Integrated approaches: Combining chronotherapy + metabolic targeting + GABAergic modulation + beta-blockade. This multi-modal approach targets the electrochemical root cause—the accumulated debt—rather than just the downstream symptoms of proliferation.

Conclusions

We propose that cancer susceptibility reflects a failure of ancient GABAergic charge regulation systems managing alpha-ketoglutarate homeostasis and circadian charge balance. Vulnerable phenotypes experience simultaneous metabolic stagnation and bio-electric instability.

Central to this framework is the recognition that alpha-ketoglutarate acts as the capacitive sink for a fundamental, quantized electrochemical deficit, and GABA acts as the voltage gate required to clear it. Cancer emerges when these regulatory failures allow this microscopic debt to accumulate into a macroscopic proliferative force.

This hypothesis aligns with established cancer biology and offers a unifying mechanism for the disparate hallmarks of cancer: they are all downstream consequences of a single, unresolved electrochemical equation.



Acknowledgments

[To be filled by author]

References

Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646-674.

Touitou Y, Reinberg A, Touitou D. Association between light at night, melatonin secretion, sleep deprivation, and the internal clock. J Pineal Res. 2017;63(4):e12371.

Reiche EMV, Nunes SOV, Morimoto HK. Stress, depression, the immune system, and cancer. Lancet Oncol. 2004;5(10):617-625.

Shelp BJ, Bown AW, McLean MD. Metabolism and functions of gamma-aminobutyric acid. Trends Plant Sci. 1999;4(11):446-452.

Watanabe M, Maemura K, Kanbara K, Tamayama T, Hayasaki H. GABA and GABA receptors in the central nervous system and other organs. Int Rev Cytol. 2002;213:1-47.

Young SZ, Bordey A. GABA's control of stem and cancer cell proliferation in adult neural and peripheral niches. Physiology. 2009;24:171-185.

Andäng M, Hjerling-Leffler J, Moliner A, et al. Histone H2AX-dependent GABA(A) receptor regulation of stem cell proliferation. Nature. 2008;451(7177):460-464.

Carey BW, Finley LW, Cross JR, Allis CD, Thompson CB. Intracellular α-ketoglutarate maintains the pluripotency of embryonic stem cells. Nature. 2015;518(7539):413-416.

Sancar A, Lindsey-Boltz LA, Kang TH, Reardon JT, Lee JH, Ozturk N. Circadian clock control of the cellular response to DNA damage. FEBS Lett. 2010;584(12):2618-2625.

Gaddameedhi S, Selby CP, Kaufmann WK, Sancar A. Control of skin cancer by the circadian rhythm. Proc Natl Acad Sci USA. 2011;108(46):18790-18795.

Cole SW, Sood AK. Molecular pathways: beta-adrenergic signaling in cancer. Clin Cancer Res. 2012;18(5):1201-1206.

Thaker PH, Han LY, Kamat AA, et al. Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma. Nat Med. 2006;12(8):939-944.

Carey BW, Finley LW, Cross JR, Allis CD, Thompson CB. Intracellular α-ketoglutarate maintains the pluripotency of embryonic stem cells. Nature. 2015;518(7539):413-416.

Tahiliani M, Koh KP, Shen Y, et al. Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science. 2009;324(5929):930-935.

Klose RJ, Kallin EM, Zhang Y. JmjC-domain-containing proteins and histone demethylation. Nat Rev Genet. 2006;7(9):715-727.

Kaelin WG Jr, Ratcliffe PJ. Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway. Mol Cell. 2008;30(4):393-402.

Dang L, White DW, Gross S, et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature. 2009;462(7274):739-744.

Yan H, Parsons DW, Jin G, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med. 2009;360(8):765-773.

Straif K, Baan R, Grosse Y, et al. Carcinogenicity of shift-work, painting, and fire-fighting. Lancet Oncol. 2007;8(12):1065-1066.

Schernhammer ES, Laden F, Speizer FE, et al. Rotating night shifts and risk of breast cancer in women participating in the nurses' health study. J Natl Cancer Inst. 2001;93(20):1563-1568.

Stevens RG. Light-at-night, circadian disruption and breast cancer: assessment of existing evidence. Int J Epidemiol. 2009;38(4):963-970.

Fu L, Pelicano H, Liu J, Huang P, Lee C. The circadian gene Period2 plays an important role in tumor suppression and DNA damage response in vivo. Cell. 2002;111(1):41-50.

Gery S, Komatsu N, Baldjyan L, Yu A, Koo D, Koeffler HP. The circadian gene per1 plays an important role in cell growth and DNA damage control in human cancer cells. Mol Cell. 2006;22(3):375-382.

Sahar S, Sassone-Corsi P. Metabolism and cancer: the circadian clock connection. Nat Rev Cancer. 2009;9(12):886-896.

Kang TH, Reardon JT, Kemp M, Sancar A. Circadian oscillation of nucleotide excision repair in mammalian brain. Proc Natl Acad Sci USA. 2009;106(8):2864-2869.

Kondratov RV, Kondratova AA, Gorbacheva VY, Vykhovanets OV, Antoch MP. Early aging and age-related pathologies in mice deficient in BMAL1. Genes Dev. 2006;20(14):1868-1873.

Antoni MH, Lutgendorf SK, Cole SW, et al. The influence of bio-behavioural factors on tumour biology. Nat Rev Cancer. 2006;6(3):240-248.

Sloan EK, Priceman SJ, Cox BF, et al. The sympathetic nervous system induces a metastatic switch in primary breast cancer. Cancer Res. 2010;70(18):7042-7052.

Lutgendorf SK, Cole S, Costanzo E, et al. Stress-related mediators stimulate vascular endothelial growth factor secretion by two ovarian cancer cell lines. Clin Cancer Res. 2003;9(12):4514-4521.

Sood AK, Bhatty R, Kamat AA, et al. Stress hormone-mediated invasion of ovarian cancer cells. Clin Cancer Res. 2006;12(2):369-375.

Kim-Fuchs C, Le CP, Pimentel MA, et al. Chronic stress accelerates pancreatic cancer growth and invasion. J Clin Invest. 2014;124(5):2059-2072.

Powe DG, Voss MJ, Zänker KS, et al. Beta-blocker drug therapy reduces secondary cancer formation in breast cancer and improves cancer specific survival. Oncotarget. 2010;1(7):628-638.

Barron TI, Connolly RM, Sharp L, Bennett K, Visvanathan K. Beta blockers and breast cancer mortality: a population-based study. J Clin Oncol. 2011;29(19):2635-2644.

Grytli HH, Fagerland MW, Fosså SD, Taskén KA, Håheim LL. Use of β-blockers is associated with prostate cancer-specific survival in prostate cancer patients on androgen deprivation therapy. Prostate. 2013;73(3):250-260.

Turcan S, Rohle D, Goenka A, et al. IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature. 2012;483(7390):479-483.

DeBerardinis RJ, Mancuso A, Daikhin E, et al. Beyond aerobic glycolysis: transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis. Proc Natl Acad Sci USA. 2007;104(49):19345-19350.

Wise DR, Thompson CB. Glutamine addiction: a new therapeutic target in cancer. Trends Biochem Sci. 2010;35(8):427-433.

Warburg O. On the origin of cancer cells. Science. 1956;123(3191):309-314.

Takehara A, Hosokawa M, Eguchi H, et al. Gamma-aminobutyric acid (GABA) stimulates pancreatic cancer growth through overexpressing GABAA receptor pi subunit. Cancer Res. 2007;67(20):9704-9712.

Maemura K, Shiraishi N, Sakagami K, et al. Proliferative effects of gamma-aminobutyric acid on the gastric cancer cell line are associated with extracellular signal-regulated kinase 1/2 activation. J Gastroenterol Hepatol. 2009;24(4):688-696.

Blanchart A, Fernando R, Häring M, et al. Endogenous GABA controls migration and differentiation of adult-born neurons in the developing mouse olfactory bulb. J Neurosci. 2006;26(45):11729-11741.

Minuk GY, Gauthier T. The effect of gamma-aminobutyric acid on hepatic regenerative activity following partial hepatectomy in rats. Gastroenterology. 1993;104(1):217-221.

Schuller HM, Al-Wadei HA, Majidi M. Gamma-aminobutyric acid, a potential tumor suppressor for small airway-derived lung adenocarcinoma. Carcinogenesis. 2008;29(10):1979-1985.

Young SZ, Bordey A. GABA's control of stem and cancer cell proliferation in adult neural and peripheral niches. Physiology (Bethesda). 2009;24:171-185.

Badalotti R, Dalmolin M, Malafaia O, Ribas Filho JM, Roesler R, Fernandes MAC, Isolan GR. Gene Expression of GABAA Receptor Subunits and Association with Patient Survival in Glioma. Brain Sci. 2024;14(3):275.

Schrader LA, Ronnekleiv-Kelly SM, Hogenesch JB, Bradfield CA, Malecki KM. Circadian disruption, clock genes, and metabolic health. J Clin Invest. 2024;134(13):e170998.

Lévi F, Okyar A, Dulong S, Innominato PF, Clairambault J. Circadian timing in cancer treatments. Annu Rev Pharmacol Toxicol. 2010;50:377-421.

Innominato PF, Roche VP, Palesh OG, Ulusakarya A, Spiegel D, Lévi FA. The circadian timing system in clinical oncology. Ann Med. 2014;46(4):191-207.

Xie L, Feng X, Huang M, Zhang K, Liu Q. Sonodynamic Therapy Combined to 2-Deoxyglucose Potentiate Cell Metastasis Inhibition of Breast Cancer. Ultrasound Med Biol. 2019;45(11):2954-2961.



